The global Parkinson’s Disease Drugs Market Size is estimated to be US$ 5.4 Billion in 2023 and is poised to register 12.6% growth over the forecast period from 2023 to 2030 to reach US $ 12.4 billion in 2030.
The market growth is driven predominantly by the global aging population has been a significant driver for the Parkinson's disease drugs market. As people age, the risk of developing Parkinson's disease increases, leading to a higher demand for effective treatments. Leading companies are focusing on Precision Medicine Personalized Therapies, Stem Cell and Regenerative Therapies, Advanced Drug Delivery Systems, Digital Health Integration, Biomarker Development, Global Market Expansion, Regulatory Pathway Improvements, and others to boost market shares in the industry.
The Parkinson's Disease Drugs Market involves the development and distribution of pharmaceuticals for treating Parkinson's disease (PD), a neurological disorder affecting movement. Factors such as an aging population and increased disease prevalence are driving market growth. Biopharmaceutical innovation, non-motor symptom management, digital health integration, and collaborative research are key trends. Challenges include disease complexity and ensuring both efficacy and safety. The market strives to develop targeted therapies, while regulatory advancements and a patient-centric approach shape its trajectory.
Biopharmaceutical innovation in the Parkinson's Disease Drugs Market refers to the development of novel drugs and therapies using advanced biological and genetic techniques. This approach aims to address the underlying causes of Parkinson's disease more effectively and achieve disease modification rather than just symptom relief. By leveraging biologics, gene therapies, and precision medicine, researchers and pharmaceutical companies are working to create treatments that target specific pathways and mechanisms involved in the disease. This innovation holds the potential to revolutionize Parkinson's treatment by providing more targeted and personalized approaches that could ultimately lead to improved patient outcomes and quality of life.
Digital health solutions in the Parkinson's Disease Drugs Market involve integrating wearable devices, mobile apps, and remote monitoring tools to track symptoms, medication adherence, and patient well-being. These technologies empower patients to actively participate in their care while generating valuable data for research and the development of more effective treatments.
Advancements in research within the Parkinson's Disease Drugs Market refer to ongoing scientific progress in understanding the disease's underlying mechanisms, causes, and treatment strategies. This includes insights into the molecular pathways involved in Parkinson's disease, potential biomarkers for early diagnosis, and innovative therapeutic targets. Research developments also encompass the exploration of neuroprotective agents, gene therapies, and personalized treatment approaches. These advancements drive the discovery and development of new and more effective drugs for managing Parkinson's disease, aiming to improve patient's lives by addressing both symptoms and disease progression.
The global Parkinson’s Disease Drugs Market is analyzed across Dopamine Agonists, Anticholinergic MAO-B inhibitors, Amantadine, Carbidopa-levodopa, COMT Inhibitors, and others. Of these, Dopamine Agonists are poised to register significant growth. Dopamine agonists in the Parkinson's Disease Drugs Market are medications designed to mimic the effects of dopamine, a neurotransmitter that plays a crucial role in movement control. These drugs activate dopamine receptors in the brain, helping to alleviate the motor symptoms of Parkinson's disease, such as tremors, rigidity, and slowness of movement.
The global Parkinson’s Disease Drugs Market is analyzed across a wide range of Distribution including Hospital, Retail, Online, and others. Of these, hospitals held a significant market share in 2023. Hospitals are central in the Parkinson's Disease Drugs Market, providing essential care for patients through specialized neurology departments offering accurate diagnosis, treatment, medication management, surgical interventions like deep brain stimulation, therapy, and patient education. Their participation in clinical trials also drives advancements in treatment options for Parkinson's disease.
By Mechanism of Action
By Distribution Channel
By Region
* List not exhaustive
Parkinson’s Disease Drugs Market Outlook 2023
1 Market Overview
1.1 Introduction to the Parkinson’s Disease Drugs Market
1.2 Scope of the Study
1.3 Research Objective
1.3.1 Key Market Scope and Segments
1.3.2 Players Covered
1.3.3 Years Considered
2 Executive Summary
2.1 2023 Parkinson’s Disease Drugs Industry- Market Statistics
3 Market Dynamics
3.1 Market Drivers
3.2 Market Challenges
3.3 Market Opportunities
3.4 Market Trends
4 Market Factor Analysis
4.1 Porter’s Five Forces
4.2 Market Entropy
4.2.1 Global Parkinson’s Disease Drugs Market Companies with Area Served
4.2.2 Products Offerings Global Parkinson’s Disease Drugs Market
5 COVID-19 Impact Analysis and Outlook Scenarios
5.1.1 Covid-19 Impact Analysis
5.1.2 Post-COVID-19 Scenario- Low Growth Case
5.1.3 Post-COVID-19 Scenario- Reference Growth Case
5.1.4 Post-COVID-19 Scenario- Low Growth Case
6 Global Parkinson’s Disease Drugs Market Trends
6.1 Global Parkinson’s Disease Drugs Revenue (USD Million) and CAGR (%) by Type (2018-2030)
6.2 Global Parkinson’s Disease Drugs Revenue (USD Million) and CAGR (%) by Applications (2018-2030)
6.3 Global Parkinson’s Disease Drugs Revenue (USD Million) and CAGR (%) by Regions (2018-2030)
7 Global Parkinson’s Disease Drugs Market Revenue (USD Million) by Type, and Applications (2018-2022)
7.1 Global Parkinson’s Disease Drugs Revenue (USD Million) by Type (2018-2022)
7.1.1 Global Parkinson’s Disease Drugs Revenue (USD Million), Market Share (%) by Type (2018-2022)
7.2 Global Parkinson’s Disease Drugs Revenue (USD Million) by Applications (2018-2022)
7.2.1 Global Parkinson’s Disease Drugs Revenue (USD Million), Market Share (%) by Applications (2018-2022)
8 Global Parkinson’s Disease Drugs Development Regional Status and Outlook
8.1 Global Parkinson’s Disease Drugs Revenue (USD Million) By Regions (2018-2022)
8.2 North America Parkinson’s Disease Drugs Revenue (USD Million) by Type, and Application (2018-2022)
8.2.1 North America Parkinson’s Disease Drugs Revenue (USD Million) by Country (2018-2022)
8.2.2 North America Parkinson’s Disease Drugs Revenue (USD Million) by Type (2018-2022)
8.2.3 North America Parkinson’s Disease Drugs Revenue (USD Million) by Applications (2018-2022)
8.3 Europe Parkinson’s Disease Drugs Revenue (USD Million), by Type, and Applications (USD Million) (2018-2022)
8.3.1 Europe Parkinson’s Disease Drugs Revenue (USD Million), by Country (2018-2022)
8.3.2 Europe Parkinson’s Disease Drugs Revenue (USD Million) by Type (2018-2022)
8.3.3 Europe Parkinson’s Disease Drugs Revenue (USD Million) by Applications (2018-2022)
8.4 Asia Pacific Parkinson’s Disease Drugs Revenue (USD Million), and Revenue (USD Million) by Type, and Applications (2018-2022)
8.4.1 Asia Pacific Parkinson’s Disease Drugs Revenue (USD Million) by Country (2018-2022)
8.4.2 Asia Pacific Parkinson’s Disease Drugs Revenue (USD Million) by Type (2018-2022)
8.4.3 Asia Pacific Parkinson’s Disease Drugs Revenue (USD Million) by Applications (2018-2022)
8.5 South America Parkinson’s Disease Drugs Revenue (USD Million), by Type, and Applications (2018-2022)
8.5.1 South America Parkinson’s Disease Drugs Revenue (USD Million), by Country (2018-2022)
8.5.2 South America Parkinson’s Disease Drugs Revenue (USD Million) by Type (2018-2022)
8.5.3 South America Parkinson’s Disease Drugs Revenue (USD Million) by Applications (2018-2022)
8.6 Middle East and Africa Parkinson’s Disease Drugs Revenue (USD Million), by Type, Technology, Application, Thickness (2018-2022)
8.6.1 Middle East and Africa Parkinson’s Disease Drugs Revenue (USD Million) by Country (2018-2022)
8.6.2 Middle East and Africa Parkinson’s Disease Drugs Revenue (USD Million) by Type (2018-2022)
8.6.3 Middle East and Africa Parkinson’s Disease Drugs Revenue (USD Million) by Applications (2018-2022)
9 Company Profiles
10 Global Parkinson’s Disease Drugs Market Revenue (USD Million), by Type, and Applications (2023-2030)
10.1 Global Parkinson’s Disease Drugs Revenue (USD Million) and Market Share (%) by Type (2023-2030)
10.1.1 Global Parkinson’s Disease Drugs Revenue (USD Million), and Market Share (%) by Type (2023-2030)
10.2 Global Parkinson’s Disease Drugs Revenue (USD Million) and Market Share (%) by Applications (2023-2030)
10.2.1 Global Parkinson’s Disease Drugs Revenue (USD Million), and Market Share (%) by Applications (2023-2030)
11 Global Parkinson’s Disease Drugs Development Regional Status and Outlook Forecast
11.1 Global Parkinson’s Disease Drugs Revenue (USD Million) By Regions (2023-2030)
11.2 North America Parkinson’s Disease Drugs Revenue (USD Million) by Type, and Applications (2023-2030)
11.2.1 North America Parkinson’s Disease Drugs Revenue (USD) Million by Country (2023-2030)
11.2.2 North America Parkinson’s Disease Drugs Revenue (USD Million), by Type (2023-2030)
11.2.3 North America Parkinson’s Disease Drugs Revenue (USD Million), Market Share (%) by Applications (2023-2030)
11.3 Europe Parkinson’s Disease Drugs Revenue (USD Million), by Type, and Applications (2023-2030)
11.3.1 Europe Parkinson’s Disease Drugs Revenue (USD Million), by Country (2023-2030)
11.3.2 Europe Parkinson’s Disease Drugs Revenue (USD Million), by Type (2023-2030)
11.3.3 Europe Parkinson’s Disease Drugs Revenue (USD Million), by Applications (2023-2030)
11.4 Asia Pacific Parkinson’s Disease Drugs Revenue (USD Million) by Type, and Applications (2023-2030)
11.4.1 Asia Pacific Parkinson’s Disease Drugs Revenue (USD Million), by Country (2023-2030)
11.4.2 Asia Pacific Parkinson’s Disease Drugs Revenue (USD Million), by Type (2023-2030)
11.4.3 Asia Pacific Parkinson’s Disease Drugs Revenue (USD Million), by Applications (2023-2030)
11.5 South America Parkinson’s Disease Drugs Revenue (USD Million), by Type, and Applications (2023-2030)
11.5.1 South America Parkinson’s Disease Drugs Revenue (USD Million), by Country (2023-2030)
11.5.2 South America Parkinson’s Disease Drugs Revenue (USD Million), by Type (2023-2030)
11.5.3 South America Parkinson’s Disease Drugs Revenue (USD Million), by Applications (2023-2030)
11.6 Middle East and Africa Parkinson’s Disease Drugs Revenue (USD Million), by Type, and Applications (2023-2030)
11.6.1 Middle East and Africa Parkinson’s Disease Drugs Revenue (USD Million), by Region (2023-2030)
11.6.2 Middle East and Africa Parkinson’s Disease Drugs Revenue (USD Million), by Type (2023-2030)
11.6.3 Middle East and Africa Parkinson’s Disease Drugs Revenue (USD Million), by Applications (2023-2030)
12 Methodology and Data Sources
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Sources
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Disclaimer
List of Tables
Table 1 Market Segmentation Analysis
Table 2 Global Parkinson’s Disease Drugs Market Companies with Areas Served
Table 3 Products Offerings Global Parkinson’s Disease Drugs Market
Table 4 Low Growth Scenario Forecasts
Table 5 Reference Case Growth Scenario
Table 6 High Growth Case Scenario
Table 7 Global Parkinson’s Disease Drugs Revenue (USD Million) And CAGR (%) By Type (2018-2030)
Table 8 Global Parkinson’s Disease Drugs Revenue (USD Million) And CAGR (%) By Applications (2018-2030)
Table 9 Global Parkinson’s Disease Drugs Revenue (USD Million) And CAGR (%) By Regions (2018-2030)
Table 10 Global Parkinson’s Disease Drugs Revenue (USD Million) By Type (2018-2022)
Table 11 Global Parkinson’s Disease Drugs Revenue Market Share (%) By Type (2018-2022)
Table 12 Global Parkinson’s Disease Drugs Revenue (USD Million) By Applications (2018-2022)
Table 13 Global Parkinson’s Disease Drugs Revenue Market Share (%) By Applications (2018-2022)
Table 14 Global Parkinson’s Disease Drugs Market Revenue (USD Million) By Regions (2018-2022)
Table 15 Global Parkinson’s Disease Drugs Market Share (%) By Regions (2018-2022)
Table 16 North America Parkinson’s Disease Drugs Revenue (USD Million) By Country (2018-2022)
Table 17 North America Parkinson’s Disease Drugs Revenue (USD Million) By Type (2018-2022)
Table 18 North America Parkinson’s Disease Drugs Revenue (USD Million) By Applications (2018-2022)
Table 19 Europe Parkinson’s Disease Drugs Revenue (USD Million) By Country (2018-2022)
Table 20 Europe Parkinson’s Disease Drugs Revenue (USD Million) By Type (2018-2022)
Table 21 Europe Parkinson’s Disease Drugs Revenue (USD Million) By Applications (2018-2022)
Table 22 Asia Pacific Parkinson’s Disease Drugs Revenue (USD Million) By Country (2018-2022)
Table 23 Asia Pacific Parkinson’s Disease Drugs Revenue (USD Million) By Type (2018-2022)
Table 24 Asia Pacific Parkinson’s Disease Drugs Revenue (USD Million) By Applications (2018-2022)
Table 25 South America Parkinson’s Disease Drugs Revenue (USD Million) By Country (2018-2022)
Table 26 South America Parkinson’s Disease Drugs Revenue (USD Million) By Type (2018-2022)
Table 27 South America Parkinson’s Disease Drugs Revenue (USD Million) By Applications (2018-2022)
Table 28 Middle East and Africa Parkinson’s Disease Drugs Revenue (USD Million) By Region (2018-2022)
Table 29 Middle East and Africa Parkinson’s Disease Drugs Revenue (USD Million) By Type (2018-2022)
Table 30 Middle East and Africa Parkinson’s Disease Drugs Revenue (USD Million) By Applications (2018-2022)
Table 31 Financial Analysis
Table 32 Global Parkinson’s Disease Drugs Revenue (USD Million) By Type (2023-2030)
Table 33 Global Parkinson’s Disease Drugs Revenue Market Share (%) By Type (2023-2030)
Table 34 Global Parkinson’s Disease Drugs Revenue (USD Million) By Applications (2023-2030)
Table 35 Global Parkinson’s Disease Drugs Revenue Market Share (%) By Applications (2023-2030)
Table 36 Global Parkinson’s Disease Drugs Market Revenue (USD Million), And Revenue (USD Million) By Regions (2023-2030)
Table 37 North America Parkinson’s Disease Drugs Revenue (USD)By Country (2023-2030)
Table 38 North America Parkinson’s Disease Drugs Revenue (USD Million) By Type (2023-2030)
Table 39 North America Parkinson’s Disease Drugs Revenue (USD Million) By Applications (2023-2030)
Table 40 Europe Parkinson’s Disease Drugs Revenue (USD Million) By Country (2023-2030)
Table 41 Europe Parkinson’s Disease Drugs Revenue (USD Million) By Type (2023-2030)
Table 42 Europe Parkinson’s Disease Drugs Revenue (USD Million) By Applications (2023-2030)
Table 43 Asia Pacific Parkinson’s Disease Drugs Revenue (USD Million) By Country (2023-2030)
Table 44 Asia Pacific Parkinson’s Disease Drugs Revenue (USD Million) By Type (2023-2030)
Table 45 Asia Pacific Parkinson’s Disease Drugs Revenue (USD Million) By Applications (2023-2030)
Table 46 South America Parkinson’s Disease Drugs Revenue (USD Million) By Country (2023-2030)
Table 47 South America Parkinson’s Disease Drugs Revenue (USD Million) By Type (2023-2030)
Table 48 South America Parkinson’s Disease Drugs Revenue (USD Million) By Applications (2023-2030)
Table 49 Middle East and Africa Parkinson’s Disease Drugs Revenue (USD Million) By Region (2023-2030)
Table 50 Middle East and Africa Parkinson’s Disease Drugs Revenue (USD Million) By Region (2023-2030)
Table 51 Middle East and Africa Parkinson’s Disease Drugs Revenue (USD Million) By Type (2023-2030)
Table 52 Middle East and Africa Parkinson’s Disease Drugs Revenue (USD Million) By Applications (2023-2030)
Table 53 Research Programs/Design for This Report
Table 54 Key Data Information from Secondary Sources
Table 55 Key Data Information from Primary Sources
List of Figures
Figure 1 Market Scope
Figure 2 Porter’s Five Forces
Figure 3 Global Parkinson’s Disease Drugs Revenue (USD Million) By Type (2018-2022)
Figure 4 Global Parkinson’s Disease Drugs Revenue Market Share (%) By Type (2022)
Figure 5 Global Parkinson’s Disease Drugs Revenue (USD Million) By Applications (2018-2022)
Figure 6 Global Parkinson’s Disease Drugs Revenue Market Share (%) By Applications (2022)
Figure 7 Global Parkinson’s Disease Drugs Market Revenue (USD Million) By Regions (2018-2022)
Figure 8 Global Parkinson’s Disease Drugs Market Share (%) By Regions (2022)
Figure 9 North America Parkinson’s Disease Drugs Revenue (USD Million) By Country (2018-2022)
Figure 10 North America Parkinson’s Disease Drugs Revenue (USD Million) By Type (2018-2022)
Figure 11 North America Parkinson’s Disease Drugs Revenue (USD Million) By Applications (2018-2022)
Figure 12 Europe Parkinson’s Disease Drugs Revenue (USD Million) By Country (2018-2022)
Figure 13 Europe Parkinson’s Disease Drugs Revenue (USD Million) By Type (2018-2022)
Figure 14 Europe Parkinson’s Disease Drugs Revenue (USD Million) By Applications (2018-2022)
Figure 15 Asia Pacific Parkinson’s Disease Drugs Revenue (USD Million) By Country (2018-2022)
Figure 16 Asia Pacific Parkinson’s Disease Drugs Revenue (USD Million) By Type (2018-2022)
Figure 17 Asia Pacific Parkinson’s Disease Drugs Revenue (USD Million) By Applications (2018-2022)
Figure 18 South America Parkinson’s Disease Drugs Revenue (USD Million) By Country (2018-2022)
Figure 19 South America Parkinson’s Disease Drugs Revenue (USD Million) By Type (2018-2022)
Figure 20 South America Parkinson’s Disease Drugs Revenue (USD Million) By Applications (2018-2022)
Figure 21 Middle East and Africa Parkinson’s Disease Drugs Revenue (USD Million) By Region (2018-2022)
Figure 22 Middle East and Africa Parkinson’s Disease Drugs Revenue (USD Million) By Type (2018-2022)
Figure 23 Middle East and Africa Parkinson’s Disease Drugs Revenue (USD Million) By Applications (2018-2022)
Figure 24 Global Parkinson’s Disease Drugs Revenue (USD Million) By Type (2023-2030)
Figure 25 Global Parkinson’s Disease Drugs Revenue Market Share (%) By Type (2030)
Figure 26 Global Parkinson’s Disease Drugs Revenue (USD Million) By Applications (2023-2030)
Figure 27 Global Parkinson’s Disease Drugs Revenue Market Share (%) By Applications (2030)
Figure 28 Global Parkinson’s Disease Drugs Market Revenue (USD Million) By Regions (2023-2030)
Figure 29 North America Parkinson’s Disease Drugs Revenue (USD Million) By Country (2023-2030)
Figure 30 North America Parkinson’s Disease Drugs Revenue (USD Million) By Type (2023-2030)
Figure 31 North America Parkinson’s Disease Drugs Revenue (USD Million) By Applications (2023-2030)
Figure 32 Europe Parkinson’s Disease Drugs Revenue (USD Million) By Country (2023-2030)
Figure 33 Europe Parkinson’s Disease Drugs Revenue (USD Million) By Type (2023-2030)
Figure 34 Europe Parkinson’s Disease Drugs Revenue (USD Million) By Applications (2023-2030)
Figure 35 Asia Pacific Parkinson’s Disease Drugs Revenue (USD Million) By Country (2023-2030)
Figure 36 Asia Pacific Parkinson’s Disease Drugs Revenue (USD Million) By Type (2023-2030)
Figure 37 Asia Pacific Parkinson’s Disease Drugs Revenue (USD Million) By Applications (2023-2030)
Figure 38 South America Parkinson’s Disease Drugs Revenue (USD Million) By Country (2023-2030)
Figure 39 South America Parkinson’s Disease Drugs Revenue (USD Million) By Type (2023-2030)
Figure 40 South America Parkinson’s Disease Drugs Revenue (USD Million) By Applications (2023-2030)
Figure 41 Middle East and Africa Parkinson’s Disease Drugs Revenue (USD Million) By Region (2023-2030)
Figure 42 Middle East and Africa Parkinson’s Disease Drugs Revenue (USD Million) By Region (2023-2030)
Figure 43 Middle East and Africa Parkinson’s Disease Drugs Revenue (USD Million) By Type (2023-2030)
Figure 44 Middle East and Africa Parkinson’s Disease Drugs Revenue (USD Million) By Applications (2023-2030)
Figure 45 Bottom-Up and Top-Down Approaches For This Report
Figure 46 Data Triangulation
By Mechanism of Action
By Distribution Channel
By Region